What is RFAR in Europe? RFAR stands for Rapid Field Alert Report. In EU terminology it’s directly linked to FSCA – Field Safety Corrective Action for medicinal products. Definition: An urgent communication to Competent Authorities and customers regarding actions taken to reduce risk of a defective medicinal product already on the market. Key EU Regulations … Read more
FDA and Global Regulatory Inspection Expectations for CPV Regulatory authorities expect Continued Process Verification (CPV) to be an integral part of the Pharmaceutical Quality System (PQS). During inspections, investigators typically evaluate whether manufacturers have established a scientifically justified and risk-based program to continuously monitor commercial manufacturing processes. Inspectors commonly review: Documented CPV procedures and responsibilities … Read more
Marketing Authorization Approval Process in Europe | Complete Guide to EU Pharmaceutical Registration Marketing Authorization Approval Process in Europe: Complete Regulatory Guide Obtaining a Marketing Authorization (MA) is one of the most important milestones in bringing a pharmaceutical product to the European market. Before any medicinal product can be marketed within the European Union (EU) … Read more
Variation Filing in Europe: A Complete Guide for Pharmaceutical Regulatory Professionals Variation Filing in Europe – Complete Regulatory Guide Once a medicinal product receives marketing authorization in the European Union (EU), its lifecycle does not end. Pharmaceutical companies frequently implement changes to manufacturing processes, analytical methods, packaging materials, manufacturing sites, quality controls, safety information, and … Read more
FMEA Application in Pharma | ICH Q9 R1 Risk Management Guide + Template 2026 Application of FMEA Tool in Pharma Risk Management: Complete ICH Q9 R1 Guide 2026 Published: April 19, 2026 | Category: Quality Risk Management | Reading Time: 8 min Failure Mode and Effects Analysis = FMEA. It’s the first QRM tool USFDA … Read more
ANDA Approval Process in USFDA: Complete Guide for Generic Drug Approval 2026 Want to launch a generic drug in USA? You need ANDA – Abbreviated New Drug Application approval from USFDA. Unlike NDA for innovators, ANDA proves your generic is same as Reference Listed Drug RLD in safety + efficacy. This guide covers ANDA vs … Read more
A pharmacopoeia constitutes a legally enforceable compilation of standards and quality criteria for medications utilized within a specific country or region. The term “Pharmacopoeia” was first used as a specific title in a publication from Basel, Switzerland, in 1561 by Dr. A. Foes, although it did not gain widespread usage until the early 17th century. … Read more
PROCESS VALIDATION Process validation is defined as the collection and evaluation of data from the process design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality product. Process validation involves a series of activities taking place over the lifecycle of the product and process. This guidance describes … Read more
This guidance provides recommendations to sponsors of new drug applications (NDA’s), abbreviated new drug applications (ANDA’s), and abbreviated antibiotic applications (AADA’s) who intend, during the post approval period, to change: SU: Scale-up during original dossier assessment. Note that this is not SU during development. Consider changes made after the Biobatch PAC: Post-PQ/post-approval, i.e. Variations. … Read more
